Cargando…

Potential of Intestinal Current Measurement for Personalized Treatment of Patients with Cystic Fibrosis

Refinement of personalized treatment of cystic fibrosis (CF) with emerging medicines targeting the CF basic defect will likely benefit from biomarkers sensitive to detect improvement of cystic fibrosis transmembrane conductance regulator (CFTR) function in individual patients. Intestinal current mea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Graeber, Simon Y., Vitzthum, Constanze, Mall, Marcus A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151208/ https://www.ncbi.nlm.nih.gov/pubmed/34066648 http://dx.doi.org/10.3390/jpm11050384

Ejemplares similares

Personalized CFTR Modulator Therapy for G85E and N1303K Homozygous Patients with Cystic Fibrosis
por: Graeber, Simon Y., et al.
Publicado: (2023)

Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis
por: Piehler, Linus, et al.
Publicado: (2023)

Effects of lumacaftor—ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in F508del homozygous patients with cystic fibrosis aged 2–11 years
por: Berges, Julian, et al.
Publicado: (2023)

Comparison of Oropharyngeal Microbiota from Children with Asthma and Cystic Fibrosis
por: Boutin, Sébastien, et al.
Publicado: (2017)

A Volatile and Dynamic Longitudinal Microbiome Is Associated With Less Reduction in Lung Function in Adolescents With Cystic Fibrosis
por: Metzger, Marisa I., et al.
Publicado: (2021)

Quantification of Phenotypic Variability of Lung Disease in Children with Cystic Fibrosis
por: Stahl, Mirjam, et al.
Publicado: (2021)

ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies
por: Mall, Marcus A.
Publicado: (2020)

TRACK-CF prospective cohort study: Understanding early cystic fibrosis lung disease
por: Steinke, Eva, et al.
Publicado: (2023)

Changes in Microbiome Dominance Are Associated With Declining Lung Function and Fluctuating Inflammation in People With Cystic Fibrosis
por: Frey, Dario L., et al.
Publicado: (2022)

Neutrophil elastase and matrix metalloproteinase 12 in cystic fibrosis lung disease
por: Wagner, Claudius J., et al.
Publicado: (2016)

Comparison of Microbiomes from Different Niches of Upper and Lower Airways in Children and Adolescents with Cystic Fibrosis
por: Boutin, Sébastien, et al.
Publicado: (2015)

Intestinal current measurement versus nasal potential difference measurements for diagnosis of cystic fibrosis: a case–control study
por: Bagheri-Hanson, Azadeh, et al.
Publicado: (2014)

Role of the SLC26A9 Chloride Channel as Disease Modifier and Potential Therapeutic Target in Cystic Fibrosis
por: Balázs, Anita, et al.
Publicado: (2018)

Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives
por: Schmidt, Béla Z, et al.
Publicado: (2016)

New Developments in Cystic Fibrosis Airway Inflammation
por: Palaniyar, Nades, et al.
Publicado: (2015)

Intestinal Inflammation and Alterations in the Gut Microbiota in Cystic Fibrosis: A Review of the Current Evidence, Pathophysiology and Future Directions
por: Tam, Rachel Y., et al.
Publicado: (2022)

Current Practices and Potential Nanotechnology Perspectives for Pain Related to Cystic Fibrosis
por: Trandafir, Laura M., et al.
Publicado: (2019)

Current Treatment Options for Cystic Fibrosis-Related Liver Disease
por: Staufer, Katharina
Publicado: (2020)

Long-term effects of lumacaftor/ivacaftor on paranasal sinus abnormalities in children with cystic fibrosis detected with magnetic resonance imaging
por: Wucherpfennig, Lena, et al.
Publicado: (2023)

Magnetic resonance imaging detects onset and association with lung disease severity of bronchial artery dilatation in cystic fibrosis
por: Leutz-Schmidt, Patricia, et al.
Publicado: (2023)

Validating organoid-derived human intestinal monolayers for personalized therapy in cystic fibrosis
por: Birimberg-Schwartz, Liron, et al.
Publicado: (2023)

The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada
por: Shemie, Genevieve, et al.
Publicado: (2021)

Current and Future Therapeutic Approaches of Exocrine Pancreatic Insufficiency in Children with Cystic Fibrosis in the Era of Personalized Medicine
por: Ritivoiu, Mirela-Elena, et al.
Publicado: (2023)

Potential of anti-inflammatory treatment for cystic fibrosis lung disease
por: Taylor-Cousar, Jennifer L, et al.
Publicado: (2010)

Cystic fibrosis transmembrane conductance regulator in COPD: a role in respiratory epithelium and beyond
por: Mall, Marcus A., et al.
Publicado: (2023)

Current and Emerging Therapies for the Treatment of Cystic Fibrosis or Mitigation of Its Symptoms
por: Murphy, Mark P., et al.
Publicado: (2016)

Non-cystic fibrosis bronchiectasis in the elderly: current perspectives
por: Quinn, Tom M, et al.
Publicado: (2018)

Cystic fibrosis: current therapeutic targets and future approaches
por: Rafeeq, Misbahuddin M., et al.
Publicado: (2017)

Cystic Fibrosis: Overview of the Current Development Trends and Innovative Therapeutic Strategies
por: Almughem, Fahad A., et al.
Publicado: (2020)

CFTR High Expresser Cells in cystic fibrosis and intestinal diseases
por: Carlos dos Reis, Diego, et al.
Publicado: (2023)

Profile of tezacaftor/ivacaftor combination and its potential in the treatment of cystic fibrosis
por: Shiferaw, Dejene, et al.
Publicado: (2019)

Imaging in non-cystic fibrosis bronchiectasis and current limitations
por: Ledda, Roberta Eufrasia, et al.
Publicado: (2021)

DMBT1 is upregulated in cystic fibrosis, affects ciliary motility, and is reduced by acetylcysteine
por: Kiefer, Alexander, et al.
Publicado: (2022)

Therapeutic Approaches for Patients with Cystic Fibrosis Not Eligible for Current CFTR Modulators
por: Fajac, Isabelle, et al.
Publicado: (2021)

Hot topics and current controversies in non-cystic fibrosis bronchiectasis
por: Severiche-Bueno, Diego, et al.
Publicado: (2019)

Current and Emerging Therapies to Combat Cystic Fibrosis Lung Infections
por: Manos, Jim
Publicado: (2021)

Gene therapy for the treatment of cystic fibrosis
por: Burney, Tabinda J, et al.
Publicado: (2012)

The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis
por: Sergeev, Valentine, et al.
Publicado: (2020)

Tobramycin administered by the TOBI(®) Podhaler(®) for persons with cystic fibrosis: a review
por: VanDevanter, Donald R, et al.
Publicado: (2011)

Intestinal Dysbiosis in Young Cystic Fibrosis Rabbits
por: Liang, Xiubin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bjvh6tblruq9mgee3r8b3dr4st